Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 3/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601754 | 0.95 | SLC22A12 (0.37) | GPR6SIGMAR1HRH2SLC22A12 | |
| SCHEMBL3597315 | 0.95 | GPR6 (0.36) | GPR6MAPTSIGMAR1HRH2SLC22A12 | |
| SCHEMBL3597969 | 0.94 | SLC22A12 (0.42) | GPR6SIGMAR1HRH2SLC22A12 | |
| SCHEMBL3596047 | 0.94 | SIGMAR1 (0.40) | GPR6SIGMAR1CHRM4HRH2 | |
| SCHEMBL3591151 | 0.94 | SLC22A12 (0.35) | GPR6SIGMAR1HRH2SLC22A12 | |
| SCHEMBL3588625 | 0.93 | HRH2 (0.37) | GPR6SIGMAR1HRH2MCHR1 | |
| SCHEMBL16327040 | 0.93 | USP14 (0.35) | GPR6MAPTSIGMAR1CHRM4HRH2 | |
| SCHEMBL3589014 | 0.92 | HRH2 (0.38) | GPR6HRH2 | |
| SCHEMBL3598918 | 0.91 | GPBAR1 (0.36) | GPR6 | |
| SCHEMBL3593372 | 0.91 | MEN1 (0.40) | SIGMAR1HRH2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | GPR6 154/4885MAPT 4708/4885SIGMAR1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.